The ADHD treatment landscape is evolving rapidly in 2026, offering new hope for patients across Florida who haven’t found success with traditional stimulant medications.
FDA Approval of Simtriyo (Centanafadine): A Game-Changer for Florida Patients
In July 2026, the FDA approved Simtriyo (centanafadine), the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD in adults and children aged 6 and older. Unlike traditional stimulants that primarily boost dopamine and norepinephrine release, this medication works as a triple reuptake inhibitor, also modulating serotonin for better emotional regulation.
Clinical trials showed significant improvements in ADHD symptoms, executive function (planning, time management, working memory), and emotional dysregulation — issues often missed by standard treatments. Common side effects include decreased appetite and headache, with low abuse potential.
Why Florida Families and Adults Are Turning to Non-Stimulant ADHD Options
From the bustling streets of Miami to the suburbs of Orlando and Tampa, many Floridians struggle with ADHD alongside anxiety or depression. Newer options like viloxazine (Qelbree) are gaining traction because they address these comorbidities effectively. Experts at the APSARD 2026 conference highlighted how these broader neurotransmitter approaches help real-world patients in everyday clinical settings.
Finding Advanced ADHD Care in Florida
If you’re searching for “ADHD treatment near me” in Florida, specialized psychiatric practices now offer these cutting-edge medications alongside comprehensive evaluations. Telehealth options make it easier than ever for patients in Jacksonville, Fort Lauderdale, or rural areas to access expert care without long commutes.
